Changes in serum potassium in people with type 2 diabetes taking sodium‐glucose co‐transporter‐2 inhibitors

Documenti analoghi

• Factors That Influence Blood Pressure Changes With the Use of Sodium‐Glucose Cotransporter 2 Inhibitors in People With Type 2 Diabetes
  di: Sara Salama, et al.
  Pubblicazione: (2026)
• ECLIPSES: Early initiation of sodium glucose cotransporter‐2 inhibitors for cardiovascular protection in patients with type 2 diabetes following acute coronary syndrome and subsequent coronary artery bypass graft surgery
  di: Lena Makortoff, et al.
  Pubblicazione: (2024)
• Albuminuria‐based stratification of end‐stage kidney disease progression and mortality with sodium‐glucose cotransporter 2 inhibitors (SGLT2i): A retrospective cohort study in type 2 diabetes and chronic kidney disease
  di: Tien‐Jyun Chang, et al.
  Pubblicazione: (2024)
• The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping review
  di: Hansa Mreyoud, et al.
  Pubblicazione: (2024)
• Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea
  di: Hee‐Jin Kim, et al.
  Pubblicazione: (2025)